Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for McAnear Justin J.. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at McAnear Justin J. har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:TXG / 10x Genomics, Inc. | 143 242 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av McAnear Justin J.. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp TXG / 10x Genomics, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i TXG / 10x Genomics, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-13 | TXG | McAnear Justin J. | 158 | 40,4855 | 158 | 40,4855 | 6 397 | 322 | 55.7900 | 2 419 | 37,82 |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel TXG / 10x Genomics, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i TXG / 10x Genomics, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av McAnear Justin J. som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-08-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −2 961 | 143 242 | −2,03 | 22,53 | −66 710 | 3 227 199 | |
2024-05-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −2 936 | 146 203 | −1,97 | 24,30 | −71 355 | 3 553 259 | |
2024-03-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 53 312 | 148 552 | 55,98 | ||||
2024-02-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 865 | 95 240 | −1,92 | 46,34 | −86 432 | 4 413 831 | |
2023-11-27 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 679 | 97 105 | −1,70 | 43,34 | −72 762 | 4 208 210 | |
2023-08-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 678 | 98 784 | −1,67 | 45,78 | −76 821 | 4 522 440 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −565 | 100 462 | −0,56 | 55,06 | −31 111 | 5 531 809 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −441 | 101 027 | −0,43 | 55,06 | −24 283 | 5 562 961 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −465 | 101 468 | −0,46 | 55,06 | −25 604 | 5 587 041 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −194 | 101 933 | −0,19 | 55,07 | −10 683 | 5 613 399 | |
2023-03-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 25 991 | 101 510 | 34,42 | ||||
2023-02-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 245 | 75 519 | −1,62 | 47,75 | −59 453 | 3 606 281 | |
2022-11-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −288 | 76 764 | −0,37 | 34,07 | −9 811 | 2 615 081 | |
2022-11-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −652 | 77 052 | −0,84 | 34,07 | −22 212 | 2 625 000 | |
2022-11-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −686 | 77 704 | −0,88 | 34,07 | −23 369 | 2 646 995 | |
2022-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 20 297 | 78 389 | 34,94 | ||||
2022-08-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −987 | 58 092 | −1,67 | 35,19 | −34 734 | 2 044 333 | |
2022-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −967 | 59 079 | −1,61 | 48,76 | −47 155 | 2 880 934 | |
2022-05-17 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
P - Purchase | 158 | 60 046 | 0,26 | 40,49 | 6 397 | 2 430 992 | |
2022-03-24 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (Right to Buy) |
A - Award | 53 392 | 53 392 | |||||
2022-03-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 21 357 | 59 888 | 55,43 | ||||
2022-02-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −288 | 38 531 | −0,74 | 78,60 | −22 637 | 3 028 513 | |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 350 159 | −2,78 | |||
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 38 819 | −1,27 | 149,18 | −74 589 | 5 790 941 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 39 319 | −1,26 | 148,04 | −74 022 | 5 820 942 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 334 | 39 819 | −3,24 | 146,92 | −195 988 | 5 850 120 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 083 | 41 153 | −9,03 | 145,96 | −595 937 | 6 006 511 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 583 | 45 236 | −7,34 | 145,16 | −520 115 | 6 566 544 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 48 819 | 25,76 | 5,04 | 50 400 | 246 048 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 360 159 | −2,70 | |||
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 38 819 | −0,26 | 155,55 | −15 555 | 6 038 295 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 38 919 | −0,51 | 153,86 | −30 772 | 5 987 984 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 119 | −0,76 | 151,80 | −45 539 | 5 938 135 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 419 | −0,76 | 151,31 | −45 394 | 5 964 674 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 39 719 | −1,24 | 150,71 | −75 357 | 5 986 209 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 40 219 | −1,47 | 149,40 | −89 643 | 6 008 920 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 302 | 40 819 | −3,09 | 148,48 | −193 321 | 6 060 805 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 42 121 | −6,02 | 147,62 | −398 563 | 6 217 725 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 536 | 44 821 | −3,31 | 146,49 | −225 014 | 6 565 994 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 462 | 46 357 | −5,04 | 145,54 | −358 323 | 6 746 867 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 48 819 | 25,76 | 5,04 | 50 400 | 246 048 |
2021-11-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −281 | 38 819 | −0,72 | 148,38 | −41 695 | 5 760 006 | |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 370 159 | −2,63 | |||
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 39 100 | −0,51 | 164,96 | −32 992 | 6 450 014 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 333 | 39 300 | −9,93 | 164,05 | −710 847 | 6 447 330 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 667 | 43 633 | −9,66 | 163,34 | −762 314 | 7 127 075 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 48 300 | −1,02 | 162,16 | −81 079 | 7 832 217 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 48 800 | −0,61 | 160,48 | −48 142 | 7 831 180 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 100 | 25,58 | 5,04 | 50 400 | 247 464 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 380 159 | −2,56 | |||
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 39 100 | −2,98 | 144,57 | −173 485 | 5 652 718 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 666 | 40 300 | −12,33 | 143,79 | −814 725 | 5 794 814 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 500 | 45 966 | −5,16 | 142,80 | −357 008 | 6 564 087 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −634 | 48 466 | −1,29 | 141,96 | −90 003 | 6 880 282 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 100 | 25,58 | 5,04 | 50 400 | 247 464 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 390 159 | −2,50 | |||
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 540 | 39 100 | −3,79 | 178,80 | −275 358 | 6 991 240 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 747 | 40 640 | −10,46 | 177,87 | −844 359 | 7 228 726 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 200 | 45 387 | −4,62 | 177,00 | −389 396 | 8 033 417 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 139 | 47 587 | −2,34 | 175,95 | −200 412 | 8 373 133 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −374 | 48 726 | −0,76 | 174,87 | −65 401 | 8 520 716 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 100 | 25,58 | 5,04 | 50 400 | 247 464 |
2021-08-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −270 | 39 100 | −0,69 | 161,85 | −43 699 | 6 328 237 | |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 400 159 | −2,44 | |||
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 370 | −0,76 | 184,52 | −55 357 | 7 264 682 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 39 670 | −1,24 | 183,30 | −91 650 | 7 271 511 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 40 170 | −1,71 | 182,16 | −127 514 | 7 317 484 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 302 | 40 870 | −5,33 | 181,31 | −417 376 | 7 410 144 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 298 | 43 172 | −5,05 | 180,29 | −414 304 | 7 783 437 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 202 | 45 470 | −4,62 | 179,28 | −394 780 | 8 151 975 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 698 | 47 672 | −3,44 | 178,35 | −302 840 | 8 502 344 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 370 | 25,40 | 5,04 | 50 400 | 248 825 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 410 159 | −2,38 | |||
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 39 370 | −0,25 | 195,82 | −19 582 | 7 709 433 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 39 470 | −1,74 | 194,81 | −136 364 | 7 688 969 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 400 | 40 170 | −3,37 | 193,76 | −271 268 | 7 783 456 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 41 570 | −1,89 | 192,95 | −154 358 | 8 020 819 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 500 | 42 370 | −3,42 | 191,73 | −287 602 | 8 123 799 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 800 | 43 870 | −6,00 | 190,66 | −533 859 | 8 364 421 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 46 670 | −5,47 | 189,85 | −512 601 | 8 860 402 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 370 | 25,40 | 5,04 | 50 400 | 248 825 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 420 159 | −2,32 | |||
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 011 | −0,76 | 180,02 | −54 007 | 7 022 889 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 39 311 | −0,51 | 179,21 | −35 842 | 7 044 826 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 511 | −0,75 | 178,07 | −53 420 | 7 035 593 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 906 | 39 811 | −6,80 | 175,77 | −510 786 | 6 997 560 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 994 | 42 717 | −4,46 | 174,93 | −348 808 | 7 472 425 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 000 | 44 711 | −2,19 | 173,94 | −173 944 | 7 777 210 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 45 711 | −1,72 | 172,85 | −138 279 | 7 901 064 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 500 | 46 511 | −5,10 | 171,59 | −428 984 | 7 980 999 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 011 | 25,63 | 5,04 | 50 400 | 247 015 |
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −281 | 39 011 | −0,72 | 162,66 | −45 707 | 6 345 514 | |
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
A - Award | 22 338 | 22 338 | |||||
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 8 935 | 39 292 | 29,43 | ||||
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 430 159 | −2,27 | |||
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 30 357 | −0,33 | 198,09 | −19 809 | 6 013 418 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 30 457 | −0,65 | 194,92 | −38 984 | 5 936 678 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −794 | 30 657 | −2,52 | 193,40 | −153 560 | 5 929 067 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 706 | 31 451 | −10,54 | 192,46 | −713 241 | 6 052 927 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 35 157 | −7,13 | 191,77 | −517 783 | 6 742 114 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 900 | 37 857 | −4,78 | 190,63 | −362 191 | 7 216 563 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 39 757 | −1,49 | 189,57 | −113 743 | 7 536 806 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 40 357 | 32,94 | 5,04 | 50 400 | 203 399 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 440 159 | −2,22 | |||
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 800 | 30 357 | −5,60 | 185,76 | −334 361 | 5 638 998 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 795 | 32 157 | −10,56 | 185,02 | −702 152 | 5 949 698 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 205 | 35 952 | −8,18 | 184,12 | −590 096 | 6 619 382 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 39 157 | −1,76 | 183,19 | −128 231 | 7 173 057 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 39 857 | −0,50 | 181,82 | −36 365 | 7 246 999 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 40 057 | −0,74 | 180,02 | −54 007 | 7 211 193 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 40 357 | 32,94 | 5,04 | 50 400 | 203 399 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −9 583 | 10 417 | −47,92 | ||||
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 9 583 | 30 357 | 46,13 | 11,48 | 110 013 | 348 498 | |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 450 159 | −2,17 | |||
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 20 774 | −0,48 | 154,82 | −15 482 | 3 216 231 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 20 874 | −1,42 | 154,14 | −46 241 | 3 217 449 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 21 174 | −1,85 | 152,08 | −60 833 | 3 220 195 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 21 574 | −3,58 | 151,22 | −120 977 | 3 262 448 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 22 374 | −5,09 | 150,22 | −180 261 | 3 360 966 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 100 | 23 574 | −4,46 | 149,43 | −164 371 | 3 522 620 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 24 674 | −0,80 | 148,08 | −29 616 | 3 653 726 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 476 | 24 874 | −5,60 | 146,88 | −216 793 | 3 653 453 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 902 | 26 350 | −6,73 | 145,90 | −277 501 | 3 844 460 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 100 | 28 252 | −3,75 | 145,03 | −159 528 | 4 097 260 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 29 352 | −1,34 | 142,48 | −56 994 | 4 182 220 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 022 | 29 752 | −3,32 | 141,25 | −144 357 | 4 202 467 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 30 774 | 48,14 | 5,04 | 50 400 | 155 101 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 460 159 | −2,13 | |||
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 20 774 | −2,35 | 178,49 | −89 247 | 3 708 034 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −910 | 21 274 | −4,10 | 177,50 | −161 525 | 3 776 139 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 777 | 22 184 | −11,13 | 176,51 | −490 171 | 3 915 718 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 213 | 24 961 | −17,28 | 175,53 | −915 027 | 4 381 352 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 30 174 | −1,95 | 174,18 | −104 509 | 5 255 759 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 30 774 | 48,14 | 5,04 | 50 400 | 155 101 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 470 159 | −2,08 | |||
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 20 774 | −0,95 | 141,91 | −28 382 | 2 948 038 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 764 | 20 974 | −7,76 | 140,78 | −248 331 | 2 952 659 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −6 036 | 22 738 | −20,98 | 139,91 | −844 525 | 3 181 380 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 000 | 28 774 | −6,50 | 139,08 | −278 152 | 4 001 776 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 30 774 | 48,14 | 5,04 | 50 400 | 155 101 |
2020-12-28 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −19 841 | 480 159 | −3,97 | ||||
2020-12-28 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 19 841 | 20 774 | 2 126,58 | 5,04 | 99 999 | 104 701 | |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 500 000 | −1,96 | |||
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 933 | −34,89 | 153,79 | −76 897 | 143 490 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 108 | 1 433 | −59,53 | 153,21 | −322 965 | 219 549 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 600 | 3 541 | −31,12 | 151,80 | −242 883 | 537 531 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 168 | 5 141 | −38,13 | 150,94 | −478 186 | 775 995 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 624 | 8 309 | −24,00 | 150,03 | −393 680 | 1 246 604 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −2 900 | 510 000 | −0,57 | |||
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 933 | −9,68 | 138,73 | −13 873 | 129 435 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 600 | 1 033 | −60,77 | 137,57 | −220 119 | 142 114 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 000 | 2 633 | −27,53 | 136,54 | −136 544 | 359 520 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 3 633 | −5,22 | 135,55 | −27 110 | 492 453 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 2 900 | 3 833 | 310,83 | 5,04 | 14 616 | 19 318 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −7 100 | 512 900 | −1,37 | |||
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 933 | −30,01 | 139,21 | −55 684 | 129 883 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 1 333 | −27,28 | 137,99 | −68 995 | 183 941 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 1 833 | −21,43 | 137,10 | −68 552 | 251 312 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 376 | 2 333 | −65,23 | 136,10 | −595 581 | 317 525 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 324 | 6 709 | −16,48 | 135,40 | −179 264 | 908 370 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 7 100 | 8 033 | 760,99 | 5,04 | 35 784 | 40 486 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 520 000 | −1,89 | |||
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 933 | −9,68 | 126,88 | −12 688 | 118 379 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 988 | 1 033 | −74,31 | 125,98 | −376 419 | 130 134 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 612 | 4 021 | −58,26 | 125,48 | −704 219 | 504 573 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 300 | 9 633 | −11,89 | 124,19 | −161 448 | 1 196 330 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 530 000 | −1,85 | |||
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −215 | 933 | −18,73 | 115,52 | −24 837 | 107 780 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 684 | 1 148 | −70,04 | 114,78 | −308 078 | 131 771 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 201 | 3 832 | −57,58 | 113,83 | −592 045 | 436 208 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 900 | 9 033 | −17,38 | 112,91 | −214 527 | 1 019 904 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 540 000 | −1,82 | |||
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 933 | −46,16 | 100,76 | −80 610 | 94 011 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −6 348 | 1 733 | −78,55 | 99,39 | −630 904 | 172 236 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 852 | 8 081 | −26,09 | 98,85 | −281 916 | 798 796 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 550 000 | −1,79 | |||
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 0 | −100,00 | 88,63 | −8 863 | |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 779 | 100 | −97,95 | 88,03 | −420 695 | 8 803 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 121 | 4 879 | −51,21 | 87,18 | −446 439 | 425 342 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 560 000 | −1,75 | |||
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 800 | 0 | −100,00 | 81,84 | −147 321 | |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 200 | 1 800 | −55,00 | 81,27 | −178 797 | 146 289 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 600 | 4 000 | −28,57 | 80,02 | −128 029 | 320 072 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 400 | 5 600 | −20,00 | 79,08 | −110 714 | 442 856 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 100 | 7 000 | −23,08 | 78,00 | −163 804 | 546 012 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −900 | 9 100 | −9,00 | 77,09 | −69 378 | 701 494 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 570 000 | −1,72 | |||
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 600 | 0 | −100,00 | 78,70 | −204 631 | |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 010 | 2 600 | −43,60 | 77,66 | −156 097 | 201 917 |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 390 | 4 610 | −53,90 | 76,64 | −413 110 | 353 327 |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-04-23 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
A - Award | 90 667 | 90 667 | |||||
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 580 000 | −1,69 | |||
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 0 | −100,00 | 59,82 | −11 964 | |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 110 | 200 | −96,23 | 58,32 | −298 025 | 11 664 |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 690 | 5 310 | −46,90 | 57,76 | −270 889 | 306 699 |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 590 000 | −1,67 | |||
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 225 | 0 | −100,00 | 69,68 | −85 359 | |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −900 | 1 225 | −42,35 | 68,26 | −61 432 | 83 616 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 2 125 | −22,02 | 66,74 | −40 047 | 141 833 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 2 725 | −20,44 | 65,72 | −46 002 | 179 079 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 940 | 3 425 | −36,16 | 64,58 | −125 280 | 221 178 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 835 | 5 365 | −34,57 | 63,65 | −180 439 | 341 465 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 800 | 8 200 | −18,00 | 62,77 | −112 993 | 514 746 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 20 000 | 20 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −20 000 | 0 | −100,00 | ||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 600 000 | 600 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −600 000 | 0 | −100,00 |